Dr. Christine Desbiens is a surgeon-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Université Laval and clinical professor at the Faculty of Medicine of Laval University. Dr. Desbiens is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.

Dr. Desbiens is the leader of the Canadian Clinical Trial Group at Saint-Sacrement Hospital of the CHU de Québec. She is also the medical director for the Centre des Maladies du Sein du CHU de Québec.

Using structured breast cancer data

The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and management of cancers and benign breast diseases.

Offer innovative treatments

The research group of the Centre des Maladies du Sein of the CHU de Québec-Laval University is one of the largest research groups in Canada offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times, and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.

Support the quality of life

The Centre des Maladies du Sein of the CHU de Québec-Laval University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life, despite the disease’s life trial.

Hôpital Saint-Sacrement
1050, chemin Sainte-Foy
Centre des maladies du sein Deschênes-Fabia
Québec, Québec
Canada G1S 4L8

Latest news

Data not available

22 entries « 1 of 5 »

Poirier E, Desbiens C, Poirier B, Boudreau D, Jacob S, Lemieux J, Doyle C, Diorio C, Hogue JC, Provencher L

In response to: Long-term overall survival of patients diagnosed with pure tubular carcinoma of the breast might be affected by increased co-morbidities.

Journal Article

J Surg Oncol, 2018, ISSN: 0022-4790.

| Links:

Poirier E, Desbiens C, Poirier B, Boudreau D, Jacob S, Lemieux J, Doyle C, Diorio C, Hogue JC, Provencher L

Characteristics and long-term survival of patients diagnosed with pure tubular carcinoma of the breast.

Journal Article

J Surg Oncol, 2017, ISSN: 0022-4790.

Abstract | Links:

Desbiens C, Filion M, Brien MC, Hogue JC, Laflamme C, Lemieux J

Impact of physical activity in group versus individual physical activity on fatigue in patients with breast cancer: A pilot study.

Journal Article

Breast, 35 , pp. 8-13, 2017, ISSN: 0960-9776.

Abstract | Links:

Tremblay-LeMay R, Hogue JC, Provencher L, Poirier B, Poirier E, Laberge S, Diorio C, Desbiens C

How Wide Should Margins Be for Phyllodes Tumors of the Breast?

Journal Article

Breast J, 23 (3), pp. 315-322, 2017, ISSN: 1075-122X.

Abstract | Links:

El-Hage A, Ruel C, Afif W, Wissanji H, Hogue JC, Desbiens C, Leblanc G, Poirier E

Metastatic pattern of invasive lobular carcinoma of the breast-Emphasis on gastric metastases.

Journal Article

J Surg Oncol, 115 (3), pp. 359, 2017, ISSN: 0022-4790.

| Links:

22 entries « 1 of 5 »

Active projects

  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31

Recently finished projects

  • A Phase III Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma, Subvention, L'Institut de recherche de la Société canadienne du cancer, from 2014-05-01 to 2017-03-31
  • MA-12: Étude randomisée à double insu visant à comparer le tamoxifène avec un placebo chez les patientes atteintes d'un cancer du sein étendu aux ganglions lymphatiques et qui ont complété une chimiothérapie adjuvante ..., Subvention, L'Institut de recherche de la Société canadienne du cancer, Subvention de recherche, from 1997-04-01 to 2017-03-31
  • NSABP Breast Cancer Treatment Protocols, Subvention, National Institute of Health (USA), Subvention de recherche, from 1997-02-01 to 2017-01-31
Data provided by the Université Laval research projects registery